Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus HYDROCORTISONE VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus HYDROCORTISONE VALERATE.
DEFLAZACORT vs HYDROCORTISONE VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
Apply a thin film to affected area twice daily. Topical use only.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Category C
Category D/X
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."